جدول الترويج Longboard Pharmaceuticals, Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. مزيد من التفاصيل| IPO date | 2021-03-12 |
|---|---|
| ISIN | US54300N1037 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.longboardpharma.com |
| Цена ао | 59.98 |
| تغير السعر يوميا: | 0% (59.98) |
|---|---|
| تغير السعر في الأسبوع: | 0% (59.98) |
| تغير السعر شهريا: | 0% (59.98) |
| تغير السعر خلال 3 أشهر: | 0% (59.98) |
| تغير السعر على مدى ستة أشهر: | +1.52% (59.08) |
| تغير السعر سنويا: | +212.4% (19.2) |
| تغير السعر على مدى 3 سنوات: | +1 078.39% (5.09) |
| تغير الأسعار منذ بداية العام: | 0% (59.98) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Cormorant Asset Management, LP | 2353141 | 7 |
| FMR, LLC | 1649503 | 4.91 |
| Price (T.Rowe) Associates Inc | 1626982 | 4.84 |
| Farallon Capital Management Llc | 1560500 | 4.64 |
| Polar Capital Holdings PLC | 1000000 | 2.98 |
| Ikarian Capital, LLC | 979462 | 2.91 |
| Integral Health Asset Management, LLC | 900000 | 2.68 |
| Blackrock Inc. | 869879 | 2.59 |
| Point72 Asset Management, L.P. | 825000 | 2.45 |
| Vanguard Group Inc | 786433 | 2.34 |
| ETF | يشارك, % | الربحية لهذا العام, % | توزيعات الأرباح, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Value ETF | 0.02069 | 197.28 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.01851 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.01676 | 596.94 | 0.72598 |
| 0.02 | 395.16 | 1.61 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Mr. Kevin R. Lind | President, CEO, Secretary & Director | 1.07M | 1976 (49 سنين) |
| Ms. Brandi L. Roberts CPA, M.B.A. | Executive VP & CFO | 662.65k | 1974 (51 سنة) |
| Dr. Randall E. Kaye M.D. | Executive VP & Chief Medical Officer | 717.95k | 1962 (63 سنة) |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Operations | N/A | |
| Mr. Steven W. Spector J.D. | Executive VP, Head of Business Development & General Counsel | N/A | 1965 (60 سنين) |
| Dr. Anne M. Danks Ph.D. | VP & Head of Nonclinical Research & Development | N/A | |
| Mr. Gus Cardenas | VP & Head of Quality Assurance | N/A | |
| Dr. Marco Peters Ph.D. | VP & Head of Translational Science | N/A | |
| Dr. Dewey McLin Ph.D. | VP & Head of Medical Affairs | N/A | |
| Ms. Megan E. Knight | VP & Head of Investor Relations |
عنوان: United States, La Jolla. CA, 4275 Executive Square - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.longboardpharma.com
موقع إلكتروني: https://www.longboardpharma.com
